Nimrata Hunt - 11 Aug 2025 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Role
Executive Vice President
Signature
/s/ Lily J. Lu, Attorney-in-Fact for Nimrata Hunt
Issuer symbol
IDXX
Transactions as of
11 Aug 2025
Net transactions value
-$488,496
Form type
4
Filing time
13 Aug 2025, 17:17:04 UTC
Previous filing
08 Aug 2025
Next filing
10 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hunt Nimrata Executive Vice President ONE IDEXX DRIVE, WESTBROOK /s/ Lily J. Lu, Attorney-in-Fact for Nimrata Hunt 13 Aug 2025 0001800619

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDXX Common Stock Sale $787,840 -1,200 -6.7% $656.53 16,807 11 Aug 2025 Direct
transaction IDXX Common Stock Options Exercise $99,826 +560 +3.3% $178.26 17,367 12 Aug 2025 Direct
transaction IDXX Common Stock Options Exercise $99,952 +483 +2.8% $206.94 17,850 12 Aug 2025 Direct
transaction IDXX Common Stock Options Exercise $99,567 +183 +1% $544.08 18,033 12 Aug 2025 Direct
holding IDXX Common Stock 160 11 Aug 2025 jointly with spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDXX Incentive Stock Option (right-to-buy) Options Exercise $0 -560 -100% $0.000000 0 12 Aug 2025 Common Stock 560 $178.26 Direct F1
transaction IDXX Incentive Stock Option (right-to-buy) Options Exercise $0 -483 -100% $0.000000 0 12 Aug 2025 Common Stock 483 $206.94 Direct F2
transaction IDXX Incentive Stock Option (right-to-buy) Options Exercise $0 -183 -100% $0.000000 0 12 Aug 2025 Common Stock 183 $544.08 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2023.
F2 Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2024.
F3 Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2025.